Corvus Pharmaceuticals Inc

Open

13.44 3.07

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.96

Max

13.36

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.4M

-14M

EPS

-0.15

Werknemers

37

EBITDA

312K

-12M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+134.25% upside

Dividenden

By Acuity

Volgende Winsten

6 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-266M

1.1B

Vorige openingsprijs

10.37

Vorige sluitingsprijs

13.44

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 jun 2026, 23:56 UTC

ETF Constituents

The Consumer Discretionary Select Sector SPDR Fund gained after-market hours, led by Amazon's 0.72% return, amid broader market weakness from inflation concerns.

26 jun 2026, 23:56 UTC

eBay Inc shares are higher in after-market trading, reaching the upper end of their one-month trading range. No specific news was identified for this movement.

26 jun 2026, 23:56 UTC

Paychex Inc shares declined in after-market trading, retracing from earlier gains. No specific company news was identified to explain the price movement.

26 jun 2026, 23:52 UTC

Mexican Consumer Confidence Index Set for Release Amid Low Sentiment and Economic Concerns on July 3, 2026.

26 jun 2026, 23:51 UTC

Event

Incyte Corp shares are higher in after-market trading following a positive recommendation for Opzelura® cream from the European Medicines Agency's Committee for Medicinal Products.

26 jun 2026, 23:51 UTC

Correlated Moves

After-market trading for the Dow Jones Index is lower, reflecting risk-off sentiment amid inflation concerns following significant price increases announced by Apple.

26 jun 2026, 23:51 UTC

Correlated Moves

The Russell 2000 Index is lower in after-market trading, reflecting broader market sentiment influenced by declines in correlated indices and inflationary concerns.

26 jun 2026, 23:51 UTC

Correlated Moves

The S&P 500 Index is trading lower in after-market hours, continuing a decline since Friday. Broader market sentiment reflects weakness in correlated assets.

26 jun 2026, 23:51 UTC

Macro News
ETF Constituents

The Financial Select Sector SPDR Fund rose in after-market hours as the U.S. Dollar declined, easing interest rate hike concerns. Key holdings also performed well.

26 jun 2026, 23:51 UTC

Global equity markets decline amid inflation concerns, with Asia's Nikkei 225 down 4.5% and U.S. mixed as consumer sentiment improves but trade deficit surges.

26 jun 2026, 23:51 UTC

U.S. equity markets show mixed performance amid global declines and inflation concerns, with key economic data on labor market conditions set for release next week.

26 jun 2026, 23:51 UTC

Asia and European equity markets decline amid tech sector concerns, while U.S. indices show mixed results despite strong earnings from Eli Lilly and Microsoft.

26 jun 2026, 23:51 UTC

European equity indices decline amid rising inflation concerns and worsening labor market conditions, with Germany's DAX down 1.3% and Japan's Nikkei 225 down 4.5%.

26 jun 2026, 23:51 UTC

News

iShares 20+ Year Treasury Bond ETF declines in after-market trading amid heightened geopolitical tensions from military actions in the Middle East.

26 jun 2026, 23:51 UTC

Correlated Moves

The VanEck J. P. Morgan EM Local Currency Bond ETF is near unchanged in after-market trading amid lower global equity indices and ongoing inflation concerns.

26 jun 2026, 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours, reflecting broader market gains. The stock remains above its 20-day moving average.

26 jun 2026, 23:51 UTC

PayPal Holdings Inc. shares are lower in after-market hours, reflecting broader market risk-off sentiment amid inflation concerns following price increases announced by Apple.

26 jun 2026, 23:51 UTC

NXP Semiconductors NV is higher in after-market hours, tracking overall market gains. No specific company news was identified to explain the movement.

26 jun 2026, 23:51 UTC

T-Mobile US Inc shares are lower in after-market hours, settling within the middle of their one-month trading range amid a broader risk-off sentiment.

26 jun 2026, 23:51 UTC

ETF Constituents

Vanguard Information Technology ETF shows modest gains after-market, driven by NVIDIA and Apple, despite mixed broader market conditions and declines in global equity indices.

26 jun 2026, 23:51 UTC

Macro News

The FTSE 100 Index is trading lower in after-market hours amid concerns over stagflation and rising long-term yields, according to UBS Asset Management.

26 jun 2026, 23:51 UTC

Macro Event
Correlated Moves

Bitcoin is higher today, influenced by positive U.S. economic data. The Goods Trade Balance deficit and Wholesale Inventories report are contributing factors to the movement.

26 jun 2026, 23:51 UTC

ETF Constituents

iShares MSCI South Korea ETF gains after market close, supported by SKM's performance. The asset remains below its 20-day moving average.

26 jun 2026, 23:51 UTC

Cognizant Technology Solutions Corp shares are higher in after-market trading, recovering from a low earlier in the session, though still below the 20-day moving average.

26 jun 2026, 23:51 UTC

Social Media
ETF Constituents

Health Care Select Sector SPDR Fund shows slight gains in after-market trading, buoyed by strong performance from top holdings and bullish sentiment toward healthcare equities.

26 jun 2026, 23:46 UTC

Cisco Systems Inc. shares are higher in after-market trading, reflecting routine activity, though the stock remains below its 20-day moving average.

26 jun 2026, 23:46 UTC

Correlated Moves

Mondelez International Inc shares are lower in after-market trading, reflecting broader declines in the consumer goods sector amid inflation concerns and risk-off sentiment.

26 jun 2026, 23:46 UTC

Correlated Moves

Cadence Design Systems shares are lower in after-market trading, reflecting broader risk-off sentiment amid inflation concerns and Synopsys Inc's recent stock decline.

26 jun 2026, 23:46 UTC

Expedia Group Inc. shares are roughly flat in after-market trading, reflecting routine performance within a broader context above its 20-day moving average.

26 jun 2026, 23:46 UTC

ETF Constituents

SPDR S&P Regional Banking ETF declines slightly after-hours, reflecting mixed U.S. market performance amid ongoing inflation concerns and declines in major global indices.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

134.25% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD  134.25%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat